Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Humblet

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patientsS Peters, V Voelter, L Zografos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Phase II study of vinorelbine in patients with androgen-independent prostate cancerS Oudard, A Caty, Y Humblet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancerS Rao, D Cunningham, A de Gramont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerE Van Cutsem, H van de Velde, P Karasek, et al.
British Journal of Cancer|October 14, 2015
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backboneJ Carrasco, M Gizzi, G Pairet, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|April 30, 2016
Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centreD Leonard, C Remue, N Abbes Orabi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2002
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical reportM Marchand, C J A Punt, S Aamdal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape studyJ-P Machiels, L Duck, B Honhon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ Y Douillard, S Siena, J Cassidy, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapyE Van Cutsem, S Siena, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patientsS Peters, V Voelter, L Zografos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Phase II study of vinorelbine in patients with androgen-independent prostate cancerS Oudard, A Caty, Y Humblet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2004
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancerS Rao, D Cunningham, A de Gramont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2004
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerE Van Cutsem, H van de Velde, P Karasek, et al.
British Journal of Cancer|October 14, 2015
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backboneJ Carrasco, M Gizzi, G Pairet, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|April 30, 2016
Lymph node ratio and surgical quality are strong prognostic factors of rectal cancer: results from a single referral centreD Leonard, C Remue, N Abbes Orabi, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2002
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical reportM Marchand, C J A Punt, S Aamdal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape studyJ-P Machiels, L Duck, B Honhon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ Y Douillard, S Siena, J Cassidy, et al.
Pageof 8